BLSM logo

BLOSSOMHILL THERAPEUTICS INC

BLSMNASDAQ
πŸ† #2930 by market capUS Equity
$15.25β–Ό $1.16 (βˆ’7.07%)
Pre-market Β· at close
πŸ””
Track BLSM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.1%
7dβ–² 4.9%
14dβ–² 8.6%
30dβ–Ό 18.2%
ytdβ€”
1yβ€”
🏦Market Cap
$443M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$15.00 – $16.54
52-Week Range
$12.93 – $27.99
Volume (shares)
3,886
Avg Volume (shares)
β€”
Shares Outstanding
29.1M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-1.7
P/S Ratio
0.0x
EPS (TTM)
$-1.65
Dividend Yield
0.00%
BLSM logo

BLOSSOMHILL THERAPEUTICS INC

BLSM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$64Mβ–² +75.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$48Mβ–² +52.3% YoY
StockOtter Β· stockotter.space

About BLOSSOMHILL THERAPEUTICS INC

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy4
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.